Researchers in Pennsylvania have used machine learning to identify biomarkers that reliably predict a patient’s response to immune checkpoint inhibitor (ICI) therapy for melanoma, the deadliest form of skin cancer. The findings could be used to identify targets to enhance responses or mitigate resistance in patients with melanoma.

ICI therapy blocks proteins on tumor or immune cells that prevent the immune system from killing cancer cells. While this treatment has shown some clinical success in patients with advanced stages of melanoma, its efficacy depends on reliable predictors of a patient’s response to the therapy. Currently, the only FDA approved biomarker for ICI melanoma treatment is the tumor mutation burden assay, but the mechanisms linking it to ICI remain unclear. 

Search Antibodies
Search Now Use our Antibody Search Tool to find the right antibody for your research. Filter
by Type, Application, Reactivity, Host, Clonality, Conjugate/Tag, and Isotype.

“This work aims to identify better and more biologically interpretable genomic predictors for immunotherapy responses,” says Noam Auslander, Ph.D., assistant professor in the Molecular & Cellular Oncogenesis Program of Wistar Institute’s Ellen and Ronald Caplan Cancer Center. “We need better biomarkers to help select patients that are more likely to respond to ICI therapy and understand what factors can help to enhance responses and increase those numbers.”

Auslander and Andrew Patterson, a graduate student in Auslander’s lab, used machine learning and publicly available de-identified clinical data to investigate why some melanoma patients responded to ICI therapy and others did not. They identified mutations in the processes of leukocyte and T-cell proliferation regulation that show potential as biomarkers with reliable and stable prediction of ICI therapy response across multiple different datasets of melanoma patients.

Patterson, first author on the paper, says the research involved training machine learning models on a dataset to predict whether a patient responds to ICI therapy, and then confirming that the model was able to continually predict response or resistance to this treatment over multiple other datasets.   “We were able to better predict if a patient would respond to ICI therapy than the current clinical standard method as well as extract biological information that could help in further understanding the mechanisms behind ICI therapy response and resistance,” Patterson says.

The findings were published recently in Nature Communications. Going forward, Auslander and Patterson intend to continue this work with the goals of increasing prediction accuracy, further understanding biological mechanisms underpinning patient resistance or responsiveness to ICI therapy and determining whether the processes used in the work can also serve as predictors of ICI treatment response for other cancer types.